Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2

被引:27
作者
De Paola, F
Ridolfi, R
Riccobon, A
Flamini, E
Barzanti, F
Granato, AM
Mordenti, GL
Medri, L
Vitali, P
Amadori, D
机构
[1] Pierantoni Hosp, Dept Med Oncol, I-47100 AUSL Forli, Italy
[2] Ist Oncol Romagnolo, I-47100 Farli, Italy
[3] Pierantoni Hosp, Dept Pathol, I-47100 AUSL Forli, Italy
关键词
TIL; tumour immunosuppression; IL-2;
D O I
10.1038/sj.bjc.6600679
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the effects of interleukin-2 (IL-2) exposure on T-cell signal transduction molecules and apoptosis markers in tumour-infiltrating lymphocytes (TIL) isolated from 20 melanoma and 16 colorectal carcinoma metastases and expanded in vitro for therapeutic reinfusion. Before IL-2 culture, TIL showed undetectable or very low levels of T-cell receptor (TCR) epsilon chain, p56(Ick), Fas ligand (FasL) and Bax expression, while Bcl-2 values were elevated. Cancer cells were characterised by low or absent Fas and Bcl-2 and high Bax expression. Notably, they also expressed FasL. After 41 - 48 days of IL-2 culture, TCR 8 chain and p56(Ick) expression of TIL rose to median values of approximately 80 and 30% positive cells, respectively (P<0.001), FasL expression was detected in 45% cells from melanomas (P<0.001) and in 3% from colorectal carcinomas (P = 0.09), and Bax-positive cells increased from 17.5 to 70% (P = 0.005). Moreover, TCR zeta chain-positive cells were significantly increased from baseline (P = 0.001), Bcl-2-positive cells dropped from 50 to 1% (P=0.007) and perforin content was high, while Fas expression was not significantly modified by IL-2 culture, In conclusion, our data suggest that the degree of immunosuppression in TIL from melanomas and colorectal carcinomas is very high, and the apoptosis markers' repertoire of cancer cells resembles that of immune-privileged tissue. Interleukin-2 culture appears to restore lymphocyte activation mechanisms, resulting in consistent FasL expression and perforin production. British Journal of Cancer (2003) 88, 320 - 326. doi: 10. 1038/sj.bjc.6600679 www.bjcancer.com (C) 2003 Cancer Research UK.
引用
收藏
页码:320 / 326
页数:7
相关论文
共 38 条
[21]  
Reichert TE, 1998, CANCER RES, V58, P5344
[22]  
Restifo Nicholas P., 1999, Current Opinion in Oncology, V11, P50, DOI 10.1097/00001622-199901000-00012
[23]   Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape [J].
Restifo, NP .
NATURE MEDICINE, 2000, 6 (05) :493-495
[24]   Adjuvant adaptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients [J].
Ridolfi, R ;
Flamini, E ;
Riccobon, A ;
De Paola, F ;
Maltoni, R ;
Gardini, A ;
Ridolfi, L ;
Medri, L ;
Poletti, G ;
Amadori, D .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 46 (04) :185-193
[25]  
Rivoltini L, 1998, J IMMUNOL, V161, P1220
[26]   TREATMENT OF PATIENTS WITH METASTATIC MELANOMA WITH AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 [J].
ROSENBERG, SA ;
YANNELLI, JR ;
YANG, JC ;
TOPALIAN, SL ;
SCHWARTZENTRUBER, DJ ;
WEBER, JS ;
PARKINSON, DR ;
SEIPP, CA ;
EINHORN, JN ;
WHITE, DE .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (15) :1159-1166
[27]   TUMOR-BEARING ANIMALS CONTAIN SUPPRESSED ANTITUMOR EFFECTORS THE FUNCTION OF WHICH CAN BE UNMASKED BY IL-2 [J].
SALVADORI, S ;
ROSENTHAL, FM ;
CRONIN, K ;
GANSBACHER, B ;
ZIER, KS .
JOURNAL OF IMMUNOTHERAPY, 1993, 14 (03) :216-220
[28]   Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines [J].
Selzer, E ;
Schlagbauer-Wadl, H ;
Okamoto, I ;
Pehamberger, H ;
Potter, R ;
Jansen, B .
MELANOMA RESEARCH, 1998, 8 (03) :197-203
[29]  
Smith D, 1998, J IMMUNOL, V160, P4159
[30]  
SULITZEANU D, 1993, ADV CANCER RES, V60, P247